FDA staff say Replimune’s melanoma trial failed to prove RP1 worksnews2026-07-28T15:05:10+00:00July 28th, 2026|Endpoints News|
Alnylam’s stock is down 30% despite a booming biotech market. Here’s whynews2026-07-28T14:00:04+00:00July 28th, 2026|Endpoints News|
Mirae raises $5.4M to turn patient texts into data for doctorsnews2026-07-28T13:15:35+00:00July 28th, 2026|Endpoints News|
Claris collects $118M to take eye drop into pivotal testing next yearnews2026-07-28T12:00:02+00:00July 28th, 2026|Endpoints News|
GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failurenews2026-07-28T11:35:41+00:00July 28th, 2026|Endpoints News|
Altimmune’s GLP-1-based shot cuts drinking in patients with alcoholismnews2026-07-28T11:00:10+00:00July 28th, 2026|Endpoints News|
Virginia federal judge says FDA should reconsider mifepristone restrictionsnews2026-07-27T18:39:32+00:00July 27th, 2026|Endpoints News|
The patent cliff is looming and CDMOs need to be prepared, Fujifilm CEO saysnews2026-07-27T18:30:58+00:00July 27th, 2026|Endpoints News|
Capricor’s DMD therapy lacks efficacy, FDA says ahead of adcommnews2026-07-27T17:40:36+00:00July 27th, 2026|Endpoints News|